Pricing Log in Create free account
Saturday 17 October 2026 Export ISPC’s income statement to Excel — free account

iSpecimen Inc.

ISPC Healthcare Diagnostics & Research

iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.

0.92 0.11 −10.68%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
3/9
Altman Z
−14.80
Beneish M
10.08
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.60
Revenue 0.47
Net Income (11.42)
Free Cash Flow (8.70)
Net Debt (4.41)
Current Ratio 0.82 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.29) (negative: loss-making)
P/S ratio 2.75
P/B ratio 0.74
Past 5Y EPS Growth —
This Y EPS Growth 28.46% (at or above 15%: strong)
Next Y EPS Growth 10.23%
Next Y revenue growth 638.21% (at or above 10%: strong)
Next 5Y EPS Growth 15.00% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −1.1×, against a ten-year median of 0.3×; over the ten years it ranged from −1.6× in 2026 to 10.8× in 2021.
P/S against its own 10 years 87.69%
10-year low 10-year high
P/B against its own 10 years 51.69%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 5 2 7 4
Receivables 3 1 0 0
Inventory — 0 — —
Other — — — —
8 4 7 4
2023 2024 2025 Q'26
Payables 4 4 5 5
ST’ Debt — — — —
Other — — — —
6 6 6 5

Compound Annual Growth %

10y 5y 3y
Sales — (25.10%) (42.97%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (46.63%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 1 1 0 0 2
’24 2 3 3 1 9
’23 3 2 3 3 10
’22 3 2 3 3 10
’21 3 3 3 3 11
’20 — 2 2 3 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (1) — — —
’25 (1) 0 (2) (1) (4)
’24 (2) (2) (1) (4) (8)
’23 (3) (2) (2) 0 (6)
’22 (1) (2) (2) 0 (6)
’21 0 (3) (6) (1) (11)
’20 — 0 0 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (1) — — —
’25 (1) 0 (3) (1) (5)
’24 (2) (2) (1) (4) (9)
’23 (6) (4) (3) (1) (11)
’22 (2) (3) (4) (3) (12)
’21 (1) (4) (7) (2) (13)
’20 — (1) (1) 1 (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (6.66) (0.98) — — —
’25 (28.40) (16.80) (19.20) (29.60) (91.20)
’24 (256.00) (152.00) (84.00) (251.20) (703.20)
’23 (216.00) (312.00) (184.00) (272.00) (984.00)
’22 (216.00) (240.00) (280.00) (192.00) (928.00)
’21 (3.39k) (696.00) (176.00) 2.59k (1.67k)
’20 — (148.80) (1.07k) (0.24) (3.98k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 3,800.00 936.00 325.60 104.88 10.40

Analyst estimates 2026–2028

Powerpack
High — — — — — 23,184.00 7,840.00 1,636.80 488.00 135.20
People
People Employees — — — — 46 59 75 53 24 7
Revenue/emp, $m — — 0.00 0.00 0.18 0.19 0.14 0.19 0.39 0.28
Income, $m
Income, $m Revenue — — 4 4 8 11 10 10 9 2
Gross margin, % — — 46.24 50.50 56.19 52.86 54.27 51.45 42.93 1.25
EBT — — (5) (5) (5) (9) (10) (11) (12) (10)
EBT margin, % — — (124.56) (113.63) (56.84) (80.48) (98.50) (111.80) (134.51) (543.68)
Net income — 0 (5) (5) (5) (9) (10) (11) (12) (10)
Depreciation — — 0 1 1 2 1 2 2 2
Per share, $
Per share, $ Revenue — — 0.67 3,582.00 6,820.08 2,062.09 937.14 878.60 521.97 16.76
Earnings — — (0.81) (4,039.80) (3,976.14) (1,672.00) (928.00) (984.00) (703.20) (91.20)
Cash flow — — (0.41) (2,233.25) (240.33) (1,975.63) (524.12) (513.95) (464.25) (36.84)
Capex — — 0.00 (2,435.25) (1,837.33) (383.94) (555.58) (419.88) (38.47) (8.69)
Free cash flow — — (0.41) (4,668.50) (2,077.67) (2,359.57) (1,079.69) (933.82) (502.72) (45.54)
Book value — — (2.81) (9,621.42) (13,420.75) 5,516.96 1,829.66 862.04 186.01 26.83
Shares, m — — 7 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 0.73 0.73 0.73 3.03 1.20 0.48 0.20 0.62
P/B — — 0.00 0.00 0.00 1.13 0.62 0.49 0.57 0.39
EV/Sales — — 1.87 1.87 1.87 0.85 (0.02) 0.24 0.28 (1.59)
EV/FCF — — (28.11) (28.11) (28.11) (0.74) 0.01 (0.18) (0.24) 0.41
Cash, $m
Cash, $m Operating cash flow — — (3) (3) 0 (11) (6) (6) (8) (4)
Capex — — (1) (3) (2) (2) (6) (5) (1) (1)
Free cash flow — — (3) (6) (2) (13) (12) (11) (9) (5)
Balance, $m
Balance, $m Working capital — — (9) (14) (19) 30 15 2 (2) 1
Total debt — — 18 11 0 3 0 — — —
Net debt — — 17 11 (1) (24) (15) (5) (2) (7)
Shareholders’ equity — — (18) (12) (16) 30 20 10 3 3
Returns, %
Returns, % ROA — — (264.41) (114.47) (89.25) (42.75) (33.96) (54.90) (99.31) (111.09)
ROIC — — 0.00 0.00 0.00 (67.64) (127.31) (147.42) (555.29) 0.00
ROE — — 25.99 22.98 18.61 (713.06) (40.90) (73.87) (191.51) (327.78)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

iSpecimen Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NDRA ENDRA Life Sciences Inc. $7.7M — (loss-making) — (loss-making) −98.80% (below 0%: shrinking) n/m +15.04% (above 0%: growing) 0.00% 0.00% Compare
XWEL XWELL, Inc. $7.5M — (loss-making) — (loss-making) −7.08% (below 0%: shrinking) n/m −43.02% (below 0%: shrinking) 41.26% (29.45%) Compare
TTOO T2 Biosystems, Inc. $6.5M — (loss-making) — (loss-making) +34.85% (above 0%: growing) n/m +53.36% (above 0%: growing) (106.60%) (511.89%) Compare
BIAF bioAffinity Technologies, Inc. $5.1M — (loss-making) — (loss-making) +18.99% (above 0%: growing) n/m −23.69% (below 0%: shrinking) 27.98% (220.77%) Compare
DMTKQ DermTech, Inc. $3.3M — (loss-making) — (loss-making) +10.58% (above 0%: growing) n/m +24.87% (above 0%: growing) 18.54% (533.37%) Compare
NOTVQ Inotiv, Inc. $2.8M — (loss-making) — (loss-making) −5.37% (below 0%: shrinking) n/m +82.66% (above 0%: growing) 20.95% (16.41%) Compare
ISPC iSpecimen Inc. $2.6M — (loss-making) — (loss-making) −78.70% (below 0%: shrinking) n/m −257.73% (below 0%: shrinking) 45.23% (897.30%)
AWHL Aspira Women's Health Inc. $2.4M — (loss-making) — (loss-making) −14.89% (below 0%: shrinking) n/m −24.57% (below 0%: shrinking) 55.28% (89.69%) Compare
PRPH ProPhase Labs, Inc. $1.2M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 22.35% (261.62%) Compare
Median of peers $4.2M — — −6.22% — +19.96% 21.65% (155.23%)

All 52 Diagnostics & Research stocks →

iSpecimen Inc. (ISPC) key facts

  • Concern: iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
  • iSpecimen Inc. (ISPC) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ISPC traded at $0.92, a market capitalization of $2.6 million.
  • Return on equity was −327.8% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −14.80 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

iSpecimen Inc. (ISPC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ISPC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com